These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1223677)

  • 1. [Activity of a new derivative of 3-hydrazinopyridazine: ISF 2123 in patients with hypertension. I].
    Ripa R; Abbondati G; Frisoni B; Tripodi G
    Minerva Cardioangiol; 1975 Nov; 23(11):735-47. PubMed ID: 1223677
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of a new derivative of 3-hydrazine pyridazine: ISF 2123 in hypertensive patients. Note 2].
    Ripa R; Abbondati G; Frisoni B; Farabegoli E; Tripodi G
    Minerva Cardioangiol; 1975 Dec; 23(12):901-5. PubMed ID: 1232586
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical pharmacology of a new hypotensive drug with peripheral vasodilating action (ISF 2123); effects of acute intravenous administration in hypertensive patients].
    Terzoli L; Bianchini C; Cornelli U; Sala C; Leonetti G; Zanchetti A
    Boll Soc Ital Cardiol; 1977; 22(7):1053-6. PubMed ID: 618241
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings: Antihypertensive activity of a new 3-hydrazinopyridazine derivative: ISF 2123.
    Carpi C; Dorigotti L
    Br J Pharmacol; 1974 Nov; 52(3):459P. PubMed ID: 4458870
    [No Abstract]   [Full Text] [Related]  

  • 5. [Binazine--a new phthalazine derivative].
    Gamski M
    Z Gesamte Inn Med; 1973 Aug; 28(15):Suppl:234-5. PubMed ID: 4765564
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound.
    Leonetti G; Terzoli L; Sala C; Bianchini C; Zanchetti A
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():461s-463s. PubMed ID: 6108817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of betaxolol (Kerlone) as a once-daily treatment for hypertension in 4685 patients.
    Djian J
    Br J Clin Pract; 1985 May; 39(5):188-91. PubMed ID: 2866790
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics and clinical effects of ISF 2123, a new antihypertensive agent.
    Pellegrini R; Abbondati G
    Farmaco Prat; 1977 Jan; 32(1):19-24. PubMed ID: 838036
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of cadralazine (ISF 2469) on water-sodium balance and on essential arterial hypertension].
    Lavezzaro GC; Gastaldo D; Noussan P; Bensoni M; Parini J; Angelino PF
    Minerva Cardioangiol; 1981 Oct; 29(10):527-34. PubMed ID: 7322375
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical effectiveness of BQ 22-708, a pyridopyridazine derivative, in the treatment of fixed essential hypertension].
    Lehmann HU; Meyer-Estorf G; Hochrein H
    Med Welt; 1978 Jun; 29(24):1007-12. PubMed ID: 672563
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cilazapril, a new ACE inhibitor, in severe arterial hypertension].
    Arcila Herrera H; Montero Cervantes L; Rivero Cárdenas NA; Osorio Guerreo MI; Flores Serrano AG; González Franco MF
    Arch Inst Cardiol Mex; 1991; 61(6):573-8. PubMed ID: 1838916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nadolol, a once daily treatment for hypertension: multi-centre clinical evaluation.
    Jackson DA
    Br J Clin Pract; 1980 Jul; 34(7):211-21. PubMed ID: 6107120
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adrenergic beta receptor blockader celiprolol in the treatment of patients with arterial hypertension].
    Kapitanenko AM; Dulin PA
    Klin Med (Mosk); 1990 Feb; 68(2):65-9. PubMed ID: 2139911
    [No Abstract]   [Full Text] [Related]  

  • 14. Longterm treatment of hypertension with penbutolol.
    Kundu SC; Bhattacherjee TD; Banerjee D; Nandi JS
    J Assoc Physicians India; 1984 Jun; 32(6):473-5. PubMed ID: 6511719
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of hypertension during a cure. Report on a study with bupranolol].
    Metzger K; Schrey A
    Med Welt; 1979 Jun; 30(25):989-91. PubMed ID: 459829
    [No Abstract]   [Full Text] [Related]  

  • 16. [Beta-blockers and arterial hypertension: comparison between nadolol and propranolol].
    Abate G; Polimeni RM; Di Peppe MC; Guarino F; Troja C; Marisi F; Cerritelli E; Brillante C; De Angelis M
    Clin Ter; 1982 Aug; 102(3):283-291. PubMed ID: 7140182
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of Cordanum in labile hypertension].
    Gerasimiuk PP; Zaporozhets TF; Slobodianik GP
    Vrach Delo; 1982 Nov; (11):29-30. PubMed ID: 6130655
    [No Abstract]   [Full Text] [Related]  

  • 18. [Monotherapy of uncomplicated essential hypertension with metoprolol].
    Mahlke R; Kühns K
    Med Welt; 1980 Feb; 31(9):333-5. PubMed ID: 7374428
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile.
    Hauger-Klevene JH; Reader C; Mayer E; Sanchez MR
    Int J Clin Pharmacol Res; 1986; 6(4):275-81. PubMed ID: 3531038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of arotinolol hydrochloride on hemodynamics, catecholamine levels and metabolism in patients with essential hypertension].
    Morimoto Y; Kasai A; Nagano K; Umino M; Kakuta Y; Iwata J; Konishi T; Hamada M; Nakano T
    Kokyu To Junkan; 1988 Mar; 36(3):311-5. PubMed ID: 2453908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.